ZMapp®

(Monocloanl Antibody) 

–First drug of Ebola virus.

-Developed by Mapp Biopharmaceutical, Inc. and LeafBio, Inc.(San Diego, CA, USA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

– First used on humans during the West Africa Ebola virus outbreak(2014).

–  FDA approved and  granted it fast track status.

–  Produced by Recombinant DNA

    Technology(RDT).

-Developed in the tobacco plant Nicotiana benthamiana.

-So it is categorized in the plantibody(plant derived antibody).

–  It is a drug cocktail of three humanized monoclonal antibodies(MAbs; c2G4, c4G7, and c13C6).

-ZMapp  binds  to three different epitopes on Ebola surface glycoprotein (GP).

References: 

1. Tran EE, Nelson EA, Bonagiri P, et al. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. J Virol. 2016;90(17):7618-7627. Published 2016 Aug 12. doi:10.1128/JVI.00406-16

2. “ZMapp™ is Granted Fast Track Status by the FDA”, September 17, 2015 – SAN DIEGO, url- https://mappbio.com/zmapp-is-granted-fast-track-status-by-the-fda/